Annual Revenue Comparison: Takeda Pharmaceutical Company Limited vs MorphoSys AG

Takeda vs. MorphoSys: A Decade of Revenue Growth

__timestampMorphoSys AGTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014639779781777824000000
Thursday, January 1, 20151062228971807378000000
Friday, January 1, 2016497435151732051000000
Sunday, January 1, 2017667908401770531000000
Monday, January 1, 2018764425052097224000000
Tuesday, January 1, 2019717553033291188000000
Wednesday, January 1, 20203276984653197812000000
Friday, January 1, 20211796000003569006000000
Saturday, January 1, 20222782670034027478000000
Sunday, January 1, 20232382783134263762000000
Monday, January 1, 20244263762000000
Loading chart...

Data in motion

A Tale of Two Giants: Takeda vs. MorphoSys

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and MorphoSys AG stand as titans, each with a unique trajectory. Over the past decade, Takeda has consistently demonstrated its dominance, with revenues soaring by approximately 140% from 2014 to 2023. In contrast, MorphoSys AG, while smaller in scale, has shown remarkable growth, with a revenue increase of nearly 270% during the same period.

Revenue Trends and Insights

Takeda's revenue peaked in 2023, reaching an impressive 4.26 trillion, reflecting its strategic expansions and acquisitions. Meanwhile, MorphoSys AG's revenue hit its zenith in 2020, with a notable 328 million, before experiencing fluctuations. The data for 2024 remains incomplete, hinting at potential shifts in the competitive landscape. This comparison underscores the dynamic nature of the pharmaceutical industry, where innovation and strategic maneuvers dictate success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025